Tevogen Approves 1-for-50 Reverse Stock Split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy TVGN?
Tevogen's Board of Directors has approved a reverse stock split of its common stock at a ratio of 50 for 1. Stockholders previously approved the reverse stock split on February 19, 2026, and provided the Board with discretion to determine the final reverse stock split ratio. The reverse stock split is being conducted to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market and is expected to become effective at 12:01 a.m. on March 6. The Company's common stock is expected to begin trading on Nasdaq on a split-adjusted basis as of the beginning of trading on March 6, under the same symbol, "TVGN", and a new CUSIP number, 88165K 200.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVGN
About TVGN
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tevogen Approves 1-for-50 Reverse Stock Split
- Reverse Split Decision: Tevogen received shareholder approval on February 19, 2026, for a 1-for-50 reverse stock split aimed at regaining compliance with the Nasdaq Global Market's $1 minimum bid requirement, set to take effect on March 6, 2026.
- Share Conversion Mechanism: Under this transaction, every 50 issued and outstanding common shares will automatically convert into one share, with no fractional shares issued, impacting over 70% of common stockholders, including directors and executives.
- Shareholder Ownership: As of January 14, 2026, Tevogen has a total of 201.42 million common shares outstanding, with directors and executives holding more than 70%, reflecting strong management confidence in the company.
- Market Compliance Objective: The primary goal of this reverse stock split is to ensure Tevogen's continued listing on Nasdaq, avoiding delisting risks due to share prices falling below $1, thereby protecting investor interests and maintaining market trust.
See More
Tevogen Signs Letter of Intent with Global CRO
- Potential Transaction Evaluation: Tevogen has signed a non-exclusive Letter of Intent with a distinguished global Contract Research Organization, which, if consummated, could significantly enhance its clinical development capabilities and facilitate the company's evolution into a revenue-generating healthcare enterprise.
- Operational Control and Revenue: CEO Ryan Saadi stated that acquiring a CRO could introduce revenue-generating service capabilities while optimizing internal trial execution, thereby strengthening earnings visibility and supporting a more capital-efficient growth model.
- Diversification Strategy Exploration: Tevogen is also actively considering other transactions focused on life sciences, although there is no assurance that any such transaction will be consummated, indicating the company's intent to expand its business scope and market influence.
- Technology-Driven Innovation: Tevogen leverages artificial intelligence and precision T cell therapy platforms to develop advanced life-saving therapies, reflecting its commitment to innovation in healthcare and improving patient access.
See More
Tevogen Enters Letter of Intent with Sciometrix for Potential Acquisition
- Strategic Acquisition Intent: Tevogen has signed a non-exclusive Letter of Intent with Sciometrix to potentially acquire a majority voting interest, which, if successful, would enhance Tevogen's revenue-generating capabilities and facilitate its transition into a healthcare enterprise.
- Integration Potential: Tevogen plans to integrate Sciometrix's Clinicus digital care management platform with Tevogen.AI, enhancing the integration of clinical development and patient engagement, thereby accelerating commercialization readiness and optimizing clinical trial efficiency.
- Market Position Enhancement: Sciometrix has become one of the top 25 digital healthcare companies in the U.S. over the past year, and Tevogen's involvement is expected to help it jump into the top 10 next year, further solidifying its competitive position in the market.
- Future Development Direction: Tevogen is also considering other life sciences-related transactions, although there is no assurance that any such transaction will be consummated, indicating a strong commitment to expanding its business and driving sustainable innovation and patient access.
See More
Tevogen Signs Letter of Intent with Sciometrix for Potential Acquisition
- Strategic Acquisition Intent: Tevogen has signed a non-exclusive Letter of Intent with Sciometrix to potentially acquire a majority voting interest, which, if successful, would transform Tevogen into a revenue-generating healthcare enterprise, enhancing its market competitiveness.
- Integration Potential: Tevogen plans to integrate Sciometrix's Clinicus digital care management platform with Tevogen.AI, enhancing the integration of clinical development and patient engagement, thereby accelerating commercialization readiness and optimizing clinical trial efficiency.
- Market Position Enhancement: Sciometrix has become one of the top 25 digital healthcare companies in the USA over the past year, and the addition of Tevogen's capabilities is expected to propel it into the top 10, further solidifying its leadership in the digital healthcare sector.
- Future Development Direction: Tevogen is also considering other life sciences-related transactions, although there is no assurance that any such transaction will be consummated, indicating its proactive approach to expanding business and improving patient access to healthcare.
See More
TEVOGEN BIO HOLDINGS INC - AGREEMENT MAY TRANSFORM TEVOGEN INTO A PROFITABLE HEALTHCARE BUSINESS
Tevogen Biologics Deal: Tevogen Holdings is involved in a deal that could significantly enhance its revenue-generating capabilities in the healthcare sector.
Focus on Healthcare: The deal emphasizes Tevogen's commitment to advancing healthcare solutions and expanding its market presence.
See More
TEVOGEN ENTERS LETTER OF INTENT TO ASSESS POSSIBLE ACQUISITION OF SCIOMETRIX AND ITS DIGITAL CARE MANAGEMENT PLATFORM, CLINICUS
Potential Acquisition: Tevogen is evaluating the potential acquisition of Sciometrics, a company specializing in digital care management solutions.
Focus on Digital Care: The acquisition aims to enhance Tevogen's capabilities in digital care management, which is increasingly important in the healthcare sector.
Strategic Growth: This move is part of Tevogen's strategy to expand its service offerings and improve patient care through innovative technology.
Market Impact: The acquisition could position Tevogen more competitively in the healthcare market, leveraging Sciometrics' expertise and platform.
See More
Tevogen Approves 1-for-50 Reverse Stock Split
- Reverse Split Decision: Tevogen received shareholder approval on February 19, 2026, for a 1-for-50 reverse stock split aimed at regaining compliance with the Nasdaq Global Market's $1 minimum bid requirement, set to take effect on March 6, 2026.
- Share Conversion Mechanism: Under this transaction, every 50 issued and outstanding common shares will automatically convert into one share, with no fractional shares issued, impacting over 70% of common stockholders, including directors and executives.
- Shareholder Ownership: As of January 14, 2026, Tevogen has a total of 201.42 million common shares outstanding, with directors and executives holding more than 70%, reflecting strong management confidence in the company.
- Market Compliance Objective: The primary goal of this reverse stock split is to ensure Tevogen's continued listing on Nasdaq, avoiding delisting risks due to share prices falling below $1, thereby protecting investor interests and maintaining market trust.
See More
Tevogen Signs Letter of Intent with Global CRO
- Potential Transaction Evaluation: Tevogen has signed a non-exclusive Letter of Intent with a distinguished global Contract Research Organization, which, if consummated, could significantly enhance its clinical development capabilities and facilitate the company's evolution into a revenue-generating healthcare enterprise.
- Operational Control and Revenue: CEO Ryan Saadi stated that acquiring a CRO could introduce revenue-generating service capabilities while optimizing internal trial execution, thereby strengthening earnings visibility and supporting a more capital-efficient growth model.
- Diversification Strategy Exploration: Tevogen is also actively considering other transactions focused on life sciences, although there is no assurance that any such transaction will be consummated, indicating the company's intent to expand its business scope and market influence.
- Technology-Driven Innovation: Tevogen leverages artificial intelligence and precision T cell therapy platforms to develop advanced life-saving therapies, reflecting its commitment to innovation in healthcare and improving patient access.
See More
Tevogen Enters Letter of Intent with Sciometrix for Potential Acquisition
- Strategic Acquisition Intent: Tevogen has signed a non-exclusive Letter of Intent with Sciometrix to potentially acquire a majority voting interest, which, if successful, would enhance Tevogen's revenue-generating capabilities and facilitate its transition into a healthcare enterprise.
- Integration Potential: Tevogen plans to integrate Sciometrix's Clinicus digital care management platform with Tevogen.AI, enhancing the integration of clinical development and patient engagement, thereby accelerating commercialization readiness and optimizing clinical trial efficiency.
- Market Position Enhancement: Sciometrix has become one of the top 25 digital healthcare companies in the U.S. over the past year, and Tevogen's involvement is expected to help it jump into the top 10 next year, further solidifying its competitive position in the market.
- Future Development Direction: Tevogen is also considering other life sciences-related transactions, although there is no assurance that any such transaction will be consummated, indicating a strong commitment to expanding its business and driving sustainable innovation and patient access.
See More
Tevogen Signs Letter of Intent with Sciometrix for Potential Acquisition
- Strategic Acquisition Intent: Tevogen has signed a non-exclusive Letter of Intent with Sciometrix to potentially acquire a majority voting interest, which, if successful, would transform Tevogen into a revenue-generating healthcare enterprise, enhancing its market competitiveness.
- Integration Potential: Tevogen plans to integrate Sciometrix's Clinicus digital care management platform with Tevogen.AI, enhancing the integration of clinical development and patient engagement, thereby accelerating commercialization readiness and optimizing clinical trial efficiency.
- Market Position Enhancement: Sciometrix has become one of the top 25 digital healthcare companies in the USA over the past year, and the addition of Tevogen's capabilities is expected to propel it into the top 10, further solidifying its leadership in the digital healthcare sector.
- Future Development Direction: Tevogen is also considering other life sciences-related transactions, although there is no assurance that any such transaction will be consummated, indicating its proactive approach to expanding business and improving patient access to healthcare.
See More
TEVOGEN BIO HOLDINGS INC - AGREEMENT MAY TRANSFORM TEVOGEN INTO A PROFITABLE HEALTHCARE BUSINESS
Tevogen Biologics Deal: Tevogen Holdings is involved in a deal that could significantly enhance its revenue-generating capabilities in the healthcare sector.
Focus on Healthcare: The deal emphasizes Tevogen's commitment to advancing healthcare solutions and expanding its market presence.
See More
TEVOGEN ENTERS LETTER OF INTENT TO ASSESS POSSIBLE ACQUISITION OF SCIOMETRIX AND ITS DIGITAL CARE MANAGEMENT PLATFORM, CLINICUS
Potential Acquisition: Tevogen is evaluating the potential acquisition of Sciometrics, a company specializing in digital care management solutions.
Focus on Digital Care: The acquisition aims to enhance Tevogen's capabilities in digital care management, which is increasingly important in the healthcare sector.
Strategic Growth: This move is part of Tevogen's strategy to expand its service offerings and improve patient care through innovative technology.
Market Impact: The acquisition could position Tevogen more competitively in the healthcare market, leveraging Sciometrics' expertise and platform.
See More
